Kornimate/medical-research-clean huggingface dataset:
interventions to improve colorectal cancer screening

Conditions: Colorectal Neoplasms

Summary: we will evaluate if we can increase colorectal cancer screening rates by directly sending screening tests to patients rather than waiting for them to come to clinic visits. we are also evaluating a new test--fecal immunochemical tests--which does not require patients to make dietary or medication changes. we will see if patients are more likely to complete these tests than the standard fecal occult blood tests.

background: colorectal cancer causes a substantial burden of suffering in the elderly va population. although colorectal cancer screening can reduce both the incidence and mortality from colorectal cancer, screening rates are low for the new mexico va health care system. objectives: we propose to use the electronic medical record and a new technology for fecal stool testing to improve screening rates and adherence to screening. methods: the electronic medical record will be used to identify patients who are eligible for screening but who do not have an immediately upcoming primary care clinic appointment. we will enroll a randomly-selected sample of 800 of these patients who have agreed to participate in the study and mail them stool tests along with instructions and educational information about the benefits of screening. we will compare the proportion of subjects who undergo colorectal cancer screening during the 3-month study period against a randomly-selected sample of 400 eligible patients who will require a clinic visit to initiate screening. because adherence for fecal occult blood tests is low, we also propose to evaluate a new screening technology--fecal immunochemical stool tests which target intact human hemoglobin. these tests can be performed without requiring patients to follow onerous dietary and medication restrictions. we will evaluate whether screening adherence (proportion completing testing) is higher with fecal immunochemical testing (n = 400) compared to the standard fecal occult blood test (n=400). we will also evaluate the yield of advanced neoplasia for each of the screening tests.

Eligibility criteria:
inclusion criteria: * eligible for stool-based colorectal cancer screening, followed in primary care clinic exclusion criteria: * need for surveillance or screening colonoscopy * limited life expectancy

Keywords: screening
comprehensive clinical decision support (cds) for the primary care of premature infants

Conditions: Prematurity

Summary: this study will use a rules-based expert system embedded in an electronic health record (ehr) to extract, interpret, and present salient facts and recommendations related to the healthcare of premature infants.

premature infants are a vulnerable population with multiple inter-related health problems that put them at risk for poor outcomes. electronic health records capture large amounts of information that may help guide decisions, but existing alert and reminder-based clinical decision support (cds) frameworks do not adequately apply multiple overlapping care guidelines to complex patient histories to produce coherent clinical recommendations. the primary objective of the study is to design and evaluate the usability of a cds intervention to improve the quality of primary care for low birth weight (lbw) and very low birth weight (vlbw) premature infants from the time of intensive care nursery discharge through 24 months corrected gestational age

Eligibility criteria:
inclusion criteria: * all clinicians from participating practices. * premature infants: receive preventive healthcare from a participating practice at least twice during the study period; (2) age less than 24 months; and (3) birth weight less than 2000 g or gestational age at birth less than 35 weeks. exclusion criteria: -residents will not eligible to participate in this study due to the fact that they receive significant ongoing education related to the inpatient and outpatient management of premature infants as part of their day-to-day training.
the effects of electroacupuncture on postoperative pain

Conditions: Periodontal Diseases; Periodontitis; Acupuncture; Electroacupuncture

Summary: in this study,the investigators aimed to examine the effect of electroacupuncture application on the amount of pain felt by patients after periodontal surgery. the main question it aims to answer is there any efficiacy of electroacupuncture application on postoperative pain reduction. participants will get periodontal flap surgery treatment with/without electroacupuncture researchers will compare ea and control groups to see if there is any relationship between acupuncture application and postoperative pain

postoperative pain is an acute pain that begins with surgical trauma and decreases over time with tissue healing. the level of pain and discomfort felt varies from person to person. the patient's sex and age, physiological and psychological structure, operation area, duration of surgery, premedication, type of anesthetic used, postoperative complications and several other environmental factors can affect this level. after the operation, especially within 48 hours, the pain increases and gradually decreases. postoperative pain may cause an increase in anxiety and general fear and concern. the stress level caused by surgical trauma in the patient delays recovery and increases mortality and morbidity. electroacupuncture (ea) applies electrical stimulation current to needles placed on acupuncture points. it is mainly used to relieve pain and provide operative analgesia. no study has been found in the literature on the pain-reducing functionality of acupuncture applications in periodontal surgical treatments. in this study, the investigators aimed to examine the effect of electroacupuncture application on the amount of pain felt by patients after periodontal surgery.

Eligibility criteria:
inclusion criteria: * absence of any systemic disease, * pregnancy or breast feeding; * not receiving anti-inflammatory drug therapy in the last 6 months, chemotherapy or radiotherapy; * having 6 mm or more probable pocket depth and clinical attachment loss in at least 4 or more teeth when called for control 6 weeks after phase i treatment exclusion criteria: * having a systemic disease such as cardiovascular, diabetes, hypertension, thyroid organ pathologies, chronic kidney failure * pregnant/breastfeeding * medication for any reason * smoker/tobacco user * other periodontal disease other than periodontitis * chronic inflammatory disease (copd, asthma)

Keywords: periodontitis acupuncture electroacupuncture
immunological response to covid-19 vaccine in patients with autoimmune and inflammatory diseases treated with immunosuppressants and/or biologics

Conditions: Autoimmune Diseases; Inflammatory Disorder

Summary: vaccination against the new coronavirus (sars-cov-2) was extended to patients at risk of severe forms of covid-19, including in particular patients with autoimmune and inflammatory diseases treated by immunosuppressants and/or biologics. in this particular population, the effectiveness of vaccines, in particular influenza and pneumococcal vaccinations, is often reduced, especially in case of treatment with rituximab and / or methotrexate. regarding the sars-cov-2 vaccine, the studies that allowed the marketing authorization of the available vaccines did not include patients treated with immunosuppressants or immunomodulators. thus, the impact of treatments on the production of neutralizing antibodies and specific t lymphocytes is not known. the goal of this study is to assess the immune response to the sars-cov-2 vaccine in patients with autoimmune and inflammatory diseases treated with immunosuppressants or immunomodulators.


Eligibility criteria:
inclusion criteria: * group 1 : * patient over 18 years old, * patient informed and not opposed to participate * patient followed for an autoimmune or inflammatory disease (vasculitis, systemic lupus, systemic sclerosis, non-infectious uveitis) * treatment with immunosuppressant and / or immunomodulator * group 2 : * patient over 18 years old, * patient informed and not opposed to participate * patient not followed for an autoimmune or inflammatory disease (vasculitis, systemic lupus, systemic sclerosis, non-infectious uveitis) * absence of treatment with immunosuppressant and / or immunomodulator exclusion criteria: * contraindication to vaccination * progressive cancer * pregnant or breastfeeding woman * current infection less than 3 weeks old * weight less than 40 kg * patient under tutor- or curator-ship * patient without health insurance

Keywords: covid-19 vaccine sars-cov2 autoimmune diseases immunosuppressants
laser enucleation of prostate (lep) versus transurethral resection of prostate (turp)

Conditions: Benign Prostatic Hyperplasia

Summary: benign prostatic hyperplasia (bph) refers to the proliferation of smooth muscle and epithelial cells of the prostate gland. the enlarged gland has the potential to result in lower urinary tract symptoms (luts) secondary to either bladder outlet obstruction or increased muscle tone and resistance, or both. for decades transurethral resection of the prostate (turp) has been the gold standard for treatment of symptomatic bph that is refractory to nonoperative management. this is a surgical intervention aimed to reduce the size of the prostate gland. however, over the past fifteen years, many alternative therapies have been introduced including laser enucleation of the prostate (lep). lep has numerous advantages including decreased blood loss and length of hospital stay as well as increased effectiveness and safety for large prostate gland sizes (\>80g).

the purpose of this study is to compare the effectiveness of turp to lep using the protouch laser technology. while turp has historically been the gold standard, lep has become more widespread and is arguably a safer and more effective therapy for the patient. turp is still widely performed because it is a traditional therapy with decades of data to support its efficacy, despite higher volume of blood loss and risk for tur syndrome. in comparison, there is some data demonstrating that holmium laser enucleation of the prostate can have similar efficacy but may have longer operative times. the protouch laser is comparable to the holmium laser but additionally provides improved hemostasis and tissue vaporization. there is little to no data comparing lep with the protouch laser to turp. this study will directly compare the efficacy of these two treatment methods by enrolling eligible subjects and comparing outcomes.

Eligibility criteria:
inclusion criteria: * male * age \> 50-80 years * prostate gland size 50-100g * failure of nonoperative therapy * ipss 8+ * fr \<15ml/s * pvr \<250 * if pvr is 250-400 then pre-operative urodynamics will be indicated * language: english, spanish, haitian creole, french, portuguese * willing to randomize exclusion criteria: * neurogenic bladder * pvr \>400ml * ipss \<8 * fr \>15ml/indwelling catheter - history of prostate cancer * history of urethral stricture or vesicourethral anastomotic stricture * unable to be placed in lithotomy position * unable to undergo general or spinal anesthesia * unable to consent * untreated or uncorrected coagulopathy

Keywords: laser enucleation of prostate (lep) transurethral resection of prostate (turp)
assessment of long-term impact post covid-19 for patients and health care professionals of the european hospital

Conditions: Covid19

Summary: the purpose of the study is to assess of long-term impact post covid for patients and health care professionals.the patients and medical staff will be followed for 2 years in order to provide clinical and paraclinical data not yet published in the literature.


Eligibility criteria:
inclusion criteria: * aged ≥ 18 years, * symptomatic covid-19 infection confirmed (by rt-pcr or elisa serology) or probable (ct criteria), * having given free and informed written consent, * being affiliated with or benefiting from a social security scheme. * patients / caregivers may be included in several ancillary studies at the same time. exclusion criteria: -subject to a measure for the protection of justice
observational study for patients at risk for chronic graft-versus-host disease

Conditions: cGVHD

Summary: the purpose of this prospective observational study is to collect data from participants who have recently had an allogenic stem cell transplant(allosct) and are at risk of chronic graft versus host disease(cgvhd)


Eligibility criteria:
inclusion criteria: * age ≥ 18 years inclusive at the time of signing the icf * allogeneic sct 90 to 180 days prior to enrollment * able to comprehend and willing to provide informed consent * willing and able to complete participant-assessment questionnaires either alone or with minimal assistance from a caregiver and/or trained site personnel exclusion criteria: * there are no exclusion criteria for this study

Keywords: chronic graft versus host disease cgvhd ma-gvhd-401 thrive gvhd chronic gvhd allogenic stem cell transplant (allosct)
the role of tranexamic acid in reducing blood transfusion requirements after cardiopulmonary bypass in neonates

Conditions: Congenital Heart Disease

Summary: this is an observational, prospective study to evaluate the role of tranexamic acid in reducing blood transfusion in neonates undergoing cardiopulmonary bypass.


Eligibility criteria:
inclusion criteria: * all neonates undergoing arterial switch or aortic arch procedure utilizing cardiopulmonary bypass (cpb). exclusion criteria: * jehovah's witness patients.
oxycodone vs fentanyl for pain treatment after laparoscopic cholecystectomy

Conditions: Pain

Summary: to evaluate the analgesic efficacy of oxycodone and fentanyl in the treatment of postoperative pain after laparoscopic cholecystectomy.


Eligibility criteria:
inclusion criteria: * planned outpatient laparoscopic cholecystectomy * \>18 years exclusion criteria: * intolerance to study drugs * treatment with mao inhibitors

Keywords: cholecystectomy, postoperative
the study will evaluate the effect of azd9164 in patients with chronic obstructive pulmonary disease

Conditions: Chronic Obstructive Pulmonary Disease

Summary: chronic obstructive pulmonary disease (copd) is a chronic respiratory condition with deteriorating lung function over the years. patients with copd experience symptoms of shortness of breath, cough and sputum production. this study is to assess the treatment effects after inhalation of three different single doses of azd9164 (100, 400 and 1200 mcg) and one single dose of tiotropium (18 mcg). one dose of placebo will be given as comparator. 25 patients are to participate in the study and all will be recruited in sweden. each patient will visit the study doctor 9 times during the study, whereof 5 visits will be overnight visits. all examinations, treatment and the follow-up is free of charge.


Eligibility criteria:
inclusion criteria: * a clinical diagnosis of copd * fev1 40 - 80% of the predicted normal value (post-bronchodilator) and post- bronchodilator fev1/fvc \< 70% exclusion criteria: * any clinically relevant abnormal findings at screening examinations * any clinically significant disease or disorder

Keywords: chronic obstructive pulmonary disease (copd) efficacy safety inhalation long-acting muscarinic receptor antagonist (lama)
one-tooth one-time (1t1t) a straightforward approach to replace missing teeth in the posterior region: a case series

Conditions: Dental Implant Failed; Dental Prosthesis Failure

Summary: this study evaluates the success rate, as the biological and prosthesis complications, of posterior single-unit implants immediately loaded with a chair side computer-aided design and manufacturing (cad-cam) composite crown, after a follow-up period of 6 months,1,2,3,4 and 5 years. complementary ex vivo analyses will be performed to evaluate the wear of restorations. the time and cost benefit of the presented digital workflow, as patient centered outcomes will also be evaluated.


Eligibility criteria:
inclusion criteria: 0 in good systemic health (asa i/ ii) * present with no contra indication against oral surgical interventions * the tooth at the implant site(s) must have been extracted or lost at least 12 weeks before the date of implantation. * at least 8 mm of bone in the vertical dimension * at least 6 mm of bone in the bucco-lingual dimension. * no need for bone augmentation procedure in any of the dimensions * full mouth plaque score (fmpi) lower or equal than 25% exclusion criteria * autoimmune disease requiring medical treatment * medical conditions requiring prolonged use of steroids * use of bisphosphonate intravenously or more then ˃ 3 years of oral use * infection (local or systemic) - patient with gingivitis or active local infection will undergo a medical treatment prior to his entrance to the study, each individual will be evaluated prior to study procedure for suitability, in case of systemic infection the evaluation will be based on medical anamneses, and if necessary will be referred to relevant medical tests. * current pregnancy or breastfeeding women * alcoholism or chronically drug abuse * immunocompromised patients * uncontrolled diabetes * smokers * prisoners * conditions or circumstances, in the opinion of the investigator, which would prevent completion of study participation or interfere with analysis of study results, such as history of non-compliance, or unreliability. local exclusion criteria: * sites treated with socket preservation techniques * untreated local inflammation * mucosal diseases or oral lesions * history of local irradiation therapy in head-neck area * persistent intraoral infection (periodontitis, caries, ...) * patients inadequate oral hygiene or unmotivated for normal home care. * removable prosthesis as an antagonist of the teeth to be replaced or absence of antagonistic teeth * severe bruxism or parafunctions

Keywords: cad-cam composite dental resin immediate dental implant loading
quality of life with esophageal stent trial

Conditions: Esophageal Cancer; Gastro-esophageal Junction Cancer

Summary: the aim of this study is to compare, specialist nurse home visits in patients with inoperable cancer in the esophagus or cardia, who are palliated with self expanding metal stent, to standard patient contact with regards to quality of life, number and character of reinterventions and cost-effectiveness.

the aim of this study is to compare, specialist nurse home visits in patients with inoperable cancer in the esophagus or gastro-esophageal junction (cardia), who are palliated with self expanding metal stent, to standard patient contact with regards to quality of life, number and character of reinterventions and cost-effectiveness.

Eligibility criteria:
inclusion criteria: * malignant obstruction of esophagus or cardia treated with sems due to non-operable disease. exclusion criteria: * mentally unable to fill out questionaire

Keywords: esophageal cancer cardia cancer health related quality of life sems home visits
pilocarpine, brimonidine, oxymetazoline (pbo) compound to control presbyopia symptoms

Conditions: Presbyopia

Summary: safety and efficacy of pilocarpine, brimonidine, oxymetazoline, hyaluronic acid, bromfenac (pbohb) ophthalmic compound to improve uncorrected near vision in healthy presbyopic patients one hour after instillation.

to determine the safety and efficacy of a novel pharmacological compound of pilocarpine, brimonidine, oxymetazoline, hyaluronic acid, bromfenac (pbohb) to improve uncorrected near vision in healthy presbyopic patients one hour after binocular instillation.

Eligibility criteria:
inclusion criteria: * healthy * presbyopic * 40 - 60 years exclusion criteria: * diabetics * previous eye surgery * previous eye disease * \> 0.50 myopia * \> 1.5 hyperopia or astigmatism
a long-term study evaluating hepatotoxicity associated with turalio™ (pexidartinib) treatment

Conditions: Hepatotoxicity; Tenosynovial Giant Cell Tumor

Summary: a study to evaluate the long-term risk of hepatic failure with turalio™ (pexidartinib) and the mechanism of liver injury based upon liver biopsy information among patients who received or are receiving turalio™ (pexidartinib) and experience hepatotoxicity.

this fda post-marketing requirement study will evaluate the long-term risk of hepatic failure with turalio™ (pexidartinib) and the mechanism of liver injury based upon liver biopsy information among patients who received or are receiving turalio™ (pexidartinib) for symptomatic tenosynovial giant cell tumor (tgct) associated with severe morbidity or functional limitations and not amenable to improvement with surgery, and who experience hepatotoxicity. a liver biopsy will be collected from enrolled patients for central laboratory analysis of macrophage and immune cell profiles to investigate possible mechanisms of the hepatotoxicity. additionally, 4 blood samples will be collected to evaluate liver function, other relevant safety tests, peripheral immune cells, and for pharmacogenomic testing. enrolled patients will be followed at least yearly for 10 years to assess long-term risk of hepatic failure.

Eligibility criteria:
inclusion criteria: * adult participants with symptomatic tgct associated with severe morbidity or functional limitations and not amenable to improvement with surgery * age ≥18 years old * emergence of at least one of the following liver test abnormalities due to turalio™ (pexidartinib) exposure: * aspartate aminotransferase (ast) or alanine aminotransferase (alt) \>3 × upper limit of normal (uln) with concurrent total bilirubin (tbil) \>2 × uln * isolated tbil \>2 × uln (excluding patients with gilbert's syndrome) * isolated ast or alt \>10 × uln * alkaline phosphatase (alp) \>2 x uln with gamma-glutamyl transferase (ggt) \>2 x uln * consent to study procedures, long-term safety follow-up, and use of data from the turalio™ (pexidartinib) risk evaluation and mitigation strategy (rems) program exclusion criteria: * not applicable

Keywords: hepatotoxicity tenosynovial giant cell tumor pexidartinib turalio™